AI Article Synopsis
- This study examined how intentionally fusing baby canine teeth (ankylosis) affects the treatment of Class III malocclusion and crossbite in young patients.
- It compared two groups of 40 patients (20 with ankylosis and 20 without), focusing on changes in cephalometric measurements after orthopedic treatment over an average of 11 months.
- Results showed that ankylosis improved the position of the jaw and facial angles, suggesting that it can be an effective strategy in orthodontic treatment.
Article Abstract
Introduction: This retrospective cephalometric study analyzed the influence of intentional ankylosis of deciduous canines in patients with Class III malocclusion and anterior crossbite, in the deciduous and early mixed dentition stages, treated by orthopedic maxillary expansion followed by maxillary protraction.
Methods: Lateral cephalograms of 40 patients were used, divided in 2 groups paired for age and gender. The Ankylosis Group was composed of 20 patients (10 boys and 10 girls) treated with induced ankylosis and presenting initial and final mean ages of 7 years 4 months and 8 years 3 months, respectively, with a mean period of maxillary protraction of 11 months. The Control Group comprised 20 patients (10 boys and 10 girls) treated without induced ankylosis, with initial and final mean ages of 7 years 8 months and 8 years 7 months, respectively, with a mean period of maxillary protraction of 11 months. Two-way analysis of variance and covariance analysis were applied to compare the initial and final cephalometric variables and the treatment changes between groups.
Results: According to the results, the variables evidencing the significant treatment changes between groups confirmed that the intentional ankylosis enhanced the sagittal response of the apical bases (Pg-NPerp) and increased the facial convexity angles (NAP and ANB).
Conclusions: The protocol involving intentional ankylosis of deciduous canines enhanced the sagittal response of the apical bases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1590/s2176-94512013000100020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rotation or change of biotherapy after TNF blocker treatment failure for axial spondyloarthritis: the ROC-SpA study, a randomised controlled study protocol.
BMJ Open
September 2024
CHU Saint-Etienne, Mines Saint-Etienne, Centre d'Investigation Clinique 1408, INSERM, SAINBIOSE U1059, University Jean Monnet Saint-Etienne, Saint-Etienne, France
Introduction: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterised by inflammatory low back pain. Non-steroidal anti-inflammatory drugs (NSAIDs) are recommended as a first treatment in axSpA. In case of inadequate response to NSAIDs, biological disease-modifying antirheumatic drugs (bDMARDs) should be introduced according to the recommendations of the European League Against Rheumatism (EULAR) and the American College of Rheumatology.
View Article and Find Full Text PDFReplantation After Dental Avulsion: A Scoping Review and Proposal of a Flow Chart.
Eur J Paediatr Dent
September 2024
Department of Surgical Science, Dentistry, Gynecology and Paediatrics, University of Verona, Paediatric Dentistry and Oral Hygiene Unit, IRCCS Sacro Cuore-Don Calabria Hospital, Negrar di Valpollicella, Verona, Italy.
Dental avulsion, the complete displacement of a tooth from its socket, is a severe dental trauma with a prevalence of 0.5% to 16% of all dental injuries. Replantation of avulsed teeth is common, yet recent studies show high failure rates and unpredictable long-term outcomes.
View Article and Find Full Text PDFSacroiliac radiographic progression over 10 years in axSpA: data from the DESIR inception cohort.
Ann Rheum Dis
June 2024
Hopital Cochin, Rheumatology, Université Paris Descartes Faculté de Médecine, Paris, France.
Objectives: To evaluate sacroiliac radiographic progression over a 10-year follow-up and determine the baseline factors associated with such progression in patients with recent-onset axial spondyloarthritis (axSpA, <3 years).
Methods: This analysis was performed in the DESIR cohort (NCT01648907). The radiographic status of the patients (radiographic axSpA (r-axSpA) vs non-radiographic axSpA (nr-axSpA)) was based on the modified New York (mNY) criteria.
A Novel Approach for Orthodontic Extrusion Prior to Intentional Replantation: A Case Report.
J Contemp Dent Pract
November 2023
Department of Orthodontics, Faculty of Dentistry, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Aim: This case report aimed to present a novel surgical technique involving orthodontics luxation of the offended tooth using miniscrew prior to performing intentional replantation (IR) to remove an extruded separated instrument that injured the inferior alveolar nerve (IAN).
Background: Intentional replantation is a dental procedure that involves extracting a tooth, managing the root canal, and then reinserting the tooth back into its socket. This procedure is typically used as a last resort when other treatment options have failed or are not possible.
Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on the progression of structural damage in the spine over 2 years in patients with radiographic axial spondyloarthritis from the randomised-controlled CONSUL trial.
Ann Rheum Dis
April 2024
Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charite Universitatsmedizin Berlin, Berlin, Germany.
Objectives: The study aimed to evaluate the effect of adding a non-steroidal anti-inflammatory drug (NSAID), celecoxib (CEL), to a tumour necrosis factor inhibitor (TNFi), golimumab (GOL), compared with TNFi monotherapy on radiographic spinal progression in patients with radiographic axial spondyloarthritis (r-axSpA) over 2 years.
Methods: R-axSpA patients, having risk factors for radiographic progression (high disease activity plus C reactive protein >5 mg/L and/or ≥1 syndesmophyte(s)), underwent a 12-week run-in phase with GOL 50 mg every 4 weeks. In the core phase (96 weeks), only patients with a good clinical response at week 12 were randomised (1:1) to GOL+CEL 200 mg two times per day (combination therapy) or GOL monotherapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!